NZ714625A - Kinase inhibitors for the treatment of cancer - Google Patents

Kinase inhibitors for the treatment of cancer

Info

Publication number
NZ714625A
NZ714625A NZ714625A NZ71462513A NZ714625A NZ 714625 A NZ714625 A NZ 714625A NZ 714625 A NZ714625 A NZ 714625A NZ 71462513 A NZ71462513 A NZ 71462513A NZ 714625 A NZ714625 A NZ 714625A
Authority
NZ
New Zealand
Prior art keywords
aad
cancer
treatment
kinase inhibitors
mesothelioma
Prior art date
Application number
NZ714625A
Inventor
David Lawson Morris
Original Assignee
Pitney Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012901199A external-priority patent/AU2012901199A0/en
Application filed by Pitney Pharmaceuticals Pty Ltd filed Critical Pitney Pharmaceuticals Pty Ltd
Publication of NZ714625A publication Critical patent/NZ714625A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton

Abstract

Disclosed are aminoacetonitrile derivatives AAD 450, AAD 907, AAD 970, AAD 1154, AAD 004, AAD 2009, AAD 1336 and AAD 1470 (as shown in drawing) that are useful in the treatment of cancer through kinase inhibition. Cancers include ovarian cancer, breast cancer, prostate cancer and mesothelioma.
NZ714625A 2012-03-23 2013-03-22 Kinase inhibitors for the treatment of cancer NZ714625A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012901199A AU2012901199A0 (en) 2012-03-23 Kinase inhibitors for the Treatment of Cancer
NZ630807A NZ630807A (en) 2012-03-23 2013-03-22 Kinase inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ714625A true NZ714625A (en) 2017-02-24

Family

ID=49221707

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ630807A NZ630807A (en) 2012-03-23 2013-03-22 Kinase inhibitors for the treatment of cancer
NZ714625A NZ714625A (en) 2012-03-23 2013-03-22 Kinase inhibitors for the treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ630807A NZ630807A (en) 2012-03-23 2013-03-22 Kinase inhibitors for the treatment of cancer

Country Status (12)

Country Link
US (2) US9308193B2 (en)
EP (2) EP2817286B1 (en)
JP (2) JP6165231B2 (en)
KR (1) KR102055176B1 (en)
CN (2) CN105534969B (en)
AU (2) AU2013234869B2 (en)
CA (1) CA2868120C (en)
ES (2) ES2685612T3 (en)
HK (2) HK1223832A1 (en)
NZ (2) NZ630807A (en)
PL (1) PL2817286T3 (en)
WO (1) WO2013138863A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ631523A (en) * 2012-08-06 2017-03-31 Pitney Pharmaceuticals Pty Ltd Compounds for the treatment of mtor pathway related diseases
WO2015061832A1 (en) * 2013-11-01 2015-05-07 Pitney Pharmaceuticals Pty Limited Pharmaceutical combinations for the treatment of cancer
JPWO2021177334A1 (en) * 2020-03-04 2021-09-10
CA3183094A1 (en) * 2020-05-11 2021-11-18 Pitney Pharmaceuticals Pty Limited Use of aminoacetonitrile compounds for the treatment of infection and disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584305A (en) * 1972-08-17 1986-04-22 Janssen Pharmaceutica N.V. Aiding the regression of neoplastic disease with 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AT408615B (en) 1998-09-15 2002-01-25 Immuno Ag NEW INFLUENCE VIRUS VACCINE COMPOSITION
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AR036054A1 (en) * 2001-06-15 2004-08-04 Novartis Ag USE OF AMINOACETONITRILE COMPOUNDS FOR THE CONTROL OF PESTS, A COMPOSITION AND A PROCESS FOR SUCH CONTROL AND A PHARMACEUTICAL COMPOSITION AGAINST PARASITES
GB0402677D0 (en) * 2003-11-06 2004-03-10 Novartis Ag Organic compounds
TW200613251A (en) * 2004-06-10 2006-05-01 Novartis Ag Organic compounds
AR054822A1 (en) 2005-07-07 2007-07-18 Sanofi Pasteur ADMISSION IMMUNE EMULSION
CN102127074A (en) * 2010-12-17 2011-07-20 中国药科大学 6-sulfamyl substituted-beta-carboline-1-ketone cell cycle protein dependent kinase 2 inhibitor and application thereof

Also Published As

Publication number Publication date
EP3061451B1 (en) 2019-05-08
AU2016204389A1 (en) 2016-07-14
EP2817286B1 (en) 2018-06-06
US9308193B2 (en) 2016-04-12
PL2817286T3 (en) 2018-11-30
JP6483736B2 (en) 2019-03-13
AU2013234869A1 (en) 2014-10-02
NZ630807A (en) 2016-04-29
HK1223832A1 (en) 2017-08-11
KR102055176B1 (en) 2019-12-12
JP6165231B2 (en) 2017-07-19
JP2017125041A (en) 2017-07-20
US20150051290A1 (en) 2015-02-19
AU2016204389B2 (en) 2018-01-25
ES2732229T3 (en) 2019-11-21
CN104364232B (en) 2017-05-31
JP2015510898A (en) 2015-04-13
ES2685612T3 (en) 2018-10-10
CA2868120C (en) 2019-02-19
WO2013138863A1 (en) 2013-09-26
EP2817286A1 (en) 2014-12-31
KR20140145604A (en) 2014-12-23
HK1205500A1 (en) 2015-12-18
CN105534969B (en) 2019-04-05
CN104364232A (en) 2015-02-18
US20160220527A1 (en) 2016-08-04
EP3061451A1 (en) 2016-08-31
CN105534969A (en) 2016-05-04
AU2013234869B2 (en) 2016-06-30
CA2868120A1 (en) 2013-09-26
EP2817286A4 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
IL291000A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
PH12015502091A1 (en) Cdc7 inhibitors
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
IL238942B (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
PL2922828T3 (en) 4,6-diamino-pyrimidine derivatives as bmi-1 inhibitors for treating cancer
NZ731797A (en) Dna-pk inhibitors
MX2019010098A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer.
MX359656B (en) Oxoquinazolinyl-butanamide derivatives.
MX364859B (en) Imidazopyrazinone derivatives.
MX2015013021A (en) 5-bromo-indirubins.
PH12015502757A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
NZ714625A (en) Kinase inhibitors for the treatment of cancer
WO2012166463A3 (en) Aminooxazole inhibitors of cyclin dependent kinases
HK1215535A1 (en) Cabazitaxel and its use for treating metastatic prostate cancers
MX363077B (en) Inhibitors of metastasis.
PH12015502756A1 (en) Combination of imidazopyridazine derivative and a mitotic agent for the treatment of cancer
EP3052116A4 (en) Methods for treating breast and other cancers by targeting argininosuccinate synthetase 1-deficiency
EP3079771A4 (en) Sgk1 inhibitors for treatment of prostate cancer
MY182434A (en) Certain chemical entities, compositions, and methods
IN2013DE02958A (en)
PT2925744T (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 MAR 2020 BY SPRUSON + FERGUSON

Effective date: 20170630

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2021 BY CPA GLOBAL

Effective date: 20200206

LAPS Patent lapsed